Affymax's Share Price Stumbles On Questionable Phase III Hematide Data
This article was originally published in The Pink Sheet Daily
Executive Summary
Phase III data for Affymax/Takeda's anemia drug for chronic kidney failure signals potential regulatory hurdles in non-dialysis use.
You may also be interested in...
Affymax Plans For Peginesatide Launch
The biotech is making plans with its Japanese partner for the launch of its new ESA that is awaiting approval.
Affymax Plans For Peginesatide Launch
The biotech is making plans with its Japanese partner for the launch of its new ESA that is awaiting approval.
CMS Begins National Coverage Determination Process For ESAs In The Renal Setting
The opening of a national coverage analysis comes with a public request for CMS to establish Medicare coverage limitations for ESA use in pre-dialysis and dialysis renal disease patient populations.